A New Era of Innovation for CAR T-cell Therapy

Molecular Therapy

Volumn 23, Issue 12, 2015, Pages 1795-

  Frederickson, Robert M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD52 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; T LYMPHOCYTE RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; B LYMPHOCYTE; CANCER CELL; CELL THERAPY; CELL TRANSPLANTATION; EDITORIAL; GENE; GENE EXPRESSION; GENE THERAPY; GRAFT VERSUS HOST REACTION; HEALTH CARE COST; HEMATOLOGIC MALIGNANCY; HUMAN; PROSTATE CANCER; RNA INTERFERENCE; T LYMPHOCYTE; TCR GENE; BIOLOGICAL THERAPY; ECONOMICS; NEOPLASMS; ORGANIZATION; PROCEDURES;

CELL- AND TISSUE-BASED THERAPY; CONGRESSES AS TOPIC; HUMANS; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL;

EID: 84951263594     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.205     Document Type: Editorial

References (3)

1. Gross, G, Waks, T and Z Eshhar. 1989. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. PNAS 86: 10024-10028.
2. June, CH, Riddell, SR and TN Schumacher. 2015. Adoptive cellular therapy: A race to the finish line. Sci Trans Med 7: 280-7
3. Qasim, W, Amrolia, PJ, Samarasinghe, S, Ghorashian, S, Zhan, H, Stafford, S et al. (2016). First clinical application of Talen engineered universal CAR19 T cells in B-ALL. Presented at the 57th annual meeting of the American Society of Hematology, Orlando, FL, 5-8 December 2015.